Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American Association for Cancer Research Vi...
March 10 2021 - 04:30PM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced
that preclinical data informing indication selection for the
clinical development of its lead macrophage program, JTX-8064, will
be presented in a poster session at the upcoming 2021 American
Association for Cancer Research (AACR) Virtual Annual Meeting
being held April 10- 15, 2021.
Poster Title: Tumor associated macrophages
and resistance to immune checkpoint blockade: Consideration
of cancer indications for the clinical development
of JTX-8064, an anti-LILRB2/ILT4 monoclonal
antibodyAuthors: Lara McGrath, Amy
Mueller, Tanzila Rahman, Jeffrey Smith, Mark
Yore, Edward Stack, Kristin O’Malley, Andrew Dunn,
Kristen Legendre, Reva Shenwai, Margaret Willer, Allison
Naumovski, Johan Baeck, and Ben Umiker (Jounce
Therapeutics, Inc.)
Session Title: Immunomodulatory Agents and InterventionsAbstract
Number: 1727 Date and Time: Saturday, April 10, 2021;
8:00am ET
About JTX-8064
JTX-8064 is a humanized IgG4 monoclonal antibody designed to
specifically bind to Leukocyte Immunoglobulin Like Receptor B2
(LILRB2/ILT4) and block interactions with its ligands. JTX-8064 is
the first tumor-associated macrophage candidate developed from
Jounce’s Translational Science Platform. Preclinical data presented
at the 2020 Society for Immunotherapy of Cancer’s Annual
Meeting and the 2019 American Association for Cancer
Research Annual Meeting support the development of JTX-8064 as
a novel immunotherapy to reprogram immune-suppressive macrophages
and enhance anti-tumor immunity. A Phase 1 clinical trial named
INNATE (NCT04669899), for JTX-8064 as a monotherapy and in
combination with either JTX-4014, or pembrolizumab, is currently
enrolling patients with advanced solid tumors.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy
company dedicated to transforming the treatment of cancer by
developing therapies that enable the immune system to attack tumors
and provide long-lasting benefits to patients through a
biomarker-driven approach. Jounce currently has multiple
development stage programs ongoing while simultaneously advancing
additional early-stage assets from its robust discovery engine
based on its Translational Science Platform. Jounce’s highest
priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist
shown to reprogram immune-suppressive tumor associated macrophages
to an anti-tumor state in preclinical studies. A Phase 1 clinical
trial, named INNATE, for JTX-8064 as a monotherapy and in
combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or
pembrolizumab is currently enrolling patients with advanced solid
tumors. Jounce’s most advanced product candidate, vopratelimab, is
a monoclonal antibody that binds to and activates ICOS, and is
currently being studied in the SELECT Phase 2 trial. JTX-4014 is a
PD-1 inhibitor intended for combination use in the INNATE and
SELECT trials and with Jounce’s broader pipeline. Additionally,
Jounce exclusively licensed worldwide rights to JTX-1811, a
monoclonal antibody targeting CCR8 and designed to selectively
deplete T regulatory cells in the tumor microenvironment, to Gilead
Sciences, Inc. For more information, please visit
www.jouncetx.com.
Cautionary Note Regarding Forward-Looking
Statements:
Various statements in this release concerning Jounce’s future
expectations, plans and prospects, including without limitation,
Jounce’s expectations regarding the timing, progress, results and
release of data for preclinical studies and clinical trials of
JTX-8064; identification, selection and enrollment of patients for
Jounce’s clinical trials; the use of JTX-4014 in combination with
Jounce’s other product candidates; may constitute forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995 and other federal
securities laws and are subject to substantial risks, uncertainties
and assumptions. You should not place reliance on these
forward-looking statements, which often include words such as
“expect,” “plan,” “will” or similar terms, variations of such terms
or the negative of those terms. Although Jounce believes that the
expectations reflected in the forward-looking statements are
reasonable, Jounce cannot guarantee such outcomes. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including,
without limitation, Jounce’s ability to successfully demonstrate
the efficacy and safety of its product candidates and future
product candidates; the preclinical and clinical results for its
product candidates, which may not support further development and
marketing approval; the potential advantages of Jounce’s product
candidates; Jounce’s ability to successfully manage its clinical
trials; the development plans of its product candidates and any
companion or complementary diagnostics; actions of regulatory
agencies, which may affect the initiation, timing and progress of
preclinical studies and clinical trials of Jounce’s product
candidates; Jounce’s ability to obtain, maintain and protect its
intellectual property; Jounce’s ability to manage operating
expenses and capital expenditures; and those risks more fully
discussed in the section entitled “Risk Factors” in Jounce’s most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission as well as discussions of potential risks,
uncertainties, and other important factors in Jounce’s subsequent
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and Jounce undertakes no
obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor and Media Contacts:Mark YoreJounce
Therapeutics, Inc.+1-857-200-1255 myore@jouncetx.com
Malin DeonJounce Therapeutics,
Inc.+1-857-259-3843mdeon@jouncetx.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2023 to Mar 2024